HER2 Support Group Forums - View Single Post - FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic ca

News · 01-23-2011, 09:20 PM

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

More...

01-23-2011, 09:20 PM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,133	FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic ca FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer. More...